SCHEMBL2905912

SCHEMBL2905912

COc1cccc2c1C(Nc1ccc3c(N)cccc3n1)CC2

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.39
ADORA2A P29274 1/20 0.39
PFKFB3 Q16875 1/20 0.39
EGFR P00533 1/20 0.39
DRD2 P14416 3/20 0.38
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
HTR1A P08908 5/20 0.36
MTNR1B P49286 1/20 0.36
HTR3A P46098 1/20 0.36
DRD3 P35462 1/20 0.36
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115247 0.94 PFKFB3 (0.41) MCHR1ADORA2APFKFB3USP2CYP1A2
SCHEMBL3412191 0.82 HTR1A (0.42) ADORA2APFKFB3EGFRDRD2HTR1A
SCHEMBL2243192 0.80 ACHE (0.42) MCHR1ADORA2APFKFB3EGFRHTR1A
SCHEMBL1616695 0.79 ALDH1A1 (0.42)
SCHEMBL1615945 0.79 GBA1 (0.48) PFKFB3EGFR
SCHEMBL1615946 0.79 GBA1 (0.48) PFKFB3EGFR
SCHEMBL2241645 0.79 PFKFB3 (0.54) MCHR1ADORA2APFKFB3EGFR
SCHEMBL2241636 0.79 PFKFB3 (0.54) MCHR1ADORA2APFKFB3EGFR
SCHEMBL1616319 0.77 MCHR1 (0.37) MCHR1PFKFB3EGFRDRD2HTR1A
SCHEMBL3401615 0.77 PFKFB3 (0.40) PFKFB3EGFRDRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099763-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-09-16 EP claimed
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-10 US claimed
WO-2008068157-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO claimed
EP-2262773-A1 2-AMINOQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
EP-2099763-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-09-16 EP disclosed
WO-2009109491-A1 2-AMINOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-10 US disclosed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US disclosed
WO-2008068157-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES HTR5A, HTR2C, HTR2B MCHR1 223/4885ADORA2A 63/4885PFKFB3 3988/4885
US-20080146567-A1 QUINOLINES HTR5A, HTR2B, HTR2C MCHR1 292/4885ADORA2A 93/4885PFKFB3 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.